Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AZ goes early for its latest $1B ADC deal with Daiichi

With the success of Enhertu as the template, AstraZeneca is putting at least a further $1 billion on the line for a much earlier stage ADC in a new deal with Daiichi Sankyo.

AstraZeneca plc (LSE:AZN; NYSE:AZN) and Daiichi Sankyo Co. Ltd. (Tokyo:4568) announced Monday a deal in which the partners will jointly develop and commercialize DS-1062 outside of Japan. DS-1062 is an antibody-drug conjugate (ADC) against

Read the full 664 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE